• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail

Section Contents Menu

  • Vaccines
  • -

    July 14, 2008 Approval Letter (1) - Fluzone

    Our STN: BL 103914/5157

    Sanofi Pasteur, Inc.
    Attention: Gary Chikami, M.D
    Discovery Drive
    Swiftwater, PA 18370

    Dear Dr. Chikami:

    We have approved your request to supplement your Biologics License Application for Influenza Virus Vaccine, to include revisions to the package insert to comply with Physician's Labeling Rule guidelines.

    Please submit final printed labeling at the time of use and include implementation information on FDA form 356h. Please provide a PDF-format electronic copy of this label. We will include the information contained in the above referenced supplement in your Biologics License Application file.

    Sincerely yours,

    --signature--

    Loris D. McVittie, Ph.D.
    Acting Director
    Division of Vaccines and Related Products Applications
    Office of Vaccines Research and Review
    Center for Biologics Evaluation and Research

    Attachment: Approved Final Draft Labeling

     

    Contact FDA

    (800) 835-4709
    (301) 827-1800
    Consumer Affairs Branch (CBER)

    Division of Communication and Consumer Affairs

    Office of Communication, Outreach and Development

    Food and Drug Administration

    1401 Rockville Pike

    Suite 200N/HFM-47

    Rockville, MD 20852-1448
    -
    -